KCR1 blocks drug HERG binding

Individualized medicine to reduce the risk of adverse side effects of certain drugs will hopefully find a place in drug development in the near future. Had this approach been available in the past there would be a number of drugs that would not have been pulled from the market due to unacceptable side effects in a small percentage of patients. In the past decade HERG blockage has arisen as a major concern, which has probably stopped a number of drugs from being developed.

In a recent paper in J. Biol. Chem. expression of the protein KCR1 (K+ channel regulatory) tends toprotect HERG from being blocked by dofetilide.  There is a “gain of function” polymorphism that is observed in the gene that codes for this protein which leads to a lower risk of acquired drug induced QT prolongation. Therefore, drugs associated with QT prolongation might be safe for people having this polymorphism.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: